CTOs on the Move

CytoDyn

www.cytodyn.com

 
CytoDyn is a biotechnology company focused on the clinical development and potential commercialization of humanized monoclonal antibodies for the treatment and prevention of Human Immunodeficiency Virus (HIV) infection. We have one of the leading monoclonal antibodies under development for HIV infection, PRO 140, which prevents viral entry into healthy T-cells by blocking the HIV co-receptor CCR5. The drug candidate is also being tested for other immunological conditions, and has been granted FDA orphan drug status for the treatment of Graft versus Host Disease (GvHD) in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) who are undergoing bone marrow ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.cytodyn.com
  • 1111 Main Street Suite 660
    Vancouver, WA USA 98660
  • Phone: 360.980.8524

Executives

Name Title Contact Details
Nitya Ray
 Chief Technology Officer Profile

Funding

CytoDyn raised $15M on 03/31/2020

Similar Companies

Delfi Diagnostics

Delfi is developing a new class of liquid biopsy tests for early detection based on altered genome-wide fragmentation profiles, also known as "fragmentomes," representing aberrant packaging of DNA in cancer cells. By applying advanced machine learning algorithms, these fragment patterns are detectable at a very low sequencing cost. Delfi is using this technology to develop highly sensitive and specific cancer detection assays intended for wide and cost-effective distribution and adoption.

ADS

ADS is a Pennsauken, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Biolin Scientific

Biolin Scientific is a Linthicum Heights, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cortexyme

Cortexyme is developing therapeutics based on data supporting a new theory of the cause of Alzheimer`s and other neurodegenerative disorders. Cortexyme is targeting a specific, undisclosed pathogen tied to neurodegeneration. The target has been validated in a number of animal models and Cortexyme is currently testing several potential lead therapeutics in preclinical studies.

Rezolute

Rezolute is a clinical stage biopharmaceutical company specializing in the development of innovative drug therapies to improve the lives of patients with metabolic and orphan diseases.